Funding for this research was provided by:
Department for Employment and Learning, Northern Ireland
Irish Department of Agriculture, Food and the Marine and Health Research Board
Received: 1 June 2020
Accepted: 10 September 2020
First Online: 11 November 2020
Ethics approval and consent to participate
: TUDA: Ethical approval was obtained from the Office for Research Ethics Committees Northern Ireland (reference number 08/NIR03/113), the Research Ethics Committee in St James’s Hospital, and the Adelaide and Meath Hospital, Dublin. All participants provided written informed consent at the time of recruitment.NANS: The study was approved by the Clinical Research Ethics Committee of the Cork Teaching Hospitals, University College Cork, and the Human Ethics Research Committee of University College Dublin. All eligible and willing participants gave their written consent according to the Helsinki declaration.
: Not applicable.
: There is a patent granted in Europe and pending elsewhere by Ward, McNulty, Strain, Horigan and Scott, on the use of riboflavin in the treatment of hypertension; the other authors have no conflicts of interest to declare.